Protiveris Installs VeriScan(TM) Biosensor System and Begins Collaboration With the Lombardi Comprehensive Cancer Center at Georgetown University

Apr 26, 2005, 01:00 ET from Protiveris Inc.

    ROCKVILLE, Md., April 26 /PRNewswire-FirstCall/ -- Protiveris Inc., a bio-
 nanotechnology company commercializing nano-mechanical technologies to
 facilitate biomolecular research, today announced that it has successfully
 completed installation of its VeriScan(TM) 3000 Biosensor System at the
 Lombardi Comprehensive Cancer Center at Georgetown University.
     Dr. Andrew Quong, who leads the Center's Division of Nanotechnology and
 Integrative Cancer Biology in the Department of Oncology, will direct a
 collaborative effort to explore the use of nanotechnologies in cancer research
 using Protiveris's microcantilever-based products.
     "This represents a significant milestone for Protiveris as it is the first
 VeriScan System collaboration with specific clinical cancer research
 applications," commented Robert Menzi, Chief Operating Officer at Protiveris.
 "Dr. Quong and his team at Lombardi are uniquely qualified to develop new
 approaches using our nano-technology products. Dr Quong understands the full
 range of scientific and technological requirements -- from engineering and
 physics to chemistry and biology -- necessary to develop successful and
 innovative approaches to cancer research."
     "This as a unique opportunity to bring the latest advances in the emerging
 field of nanotechnology to cancer diagnosis and therapeutic stratification,"
 added Dr Quong.  "The Protiveris VeriScan Biosensor System affords us the
 potential to perform highly sensitive multiplexed assays for both laboratory
 and clinical use on a stable, well engineered platform."
     The VeriScan 3000 protein biochip and optical reader utilize arrays of
 microcantilevers with customizable surfaces to measure, label-free and in
 real-time, multiplex and distinct protein, antibody, antigen, or DNA
 biomolecular interactions. Protiveris is currently installing this system in
 forward-looking research facilities in the United States and Europe.
     About Protiveris, Inc.
     Protiveris is committed to establishing the standard of performance for
 proteomic research tools. The VeriScan(TM) 3000 bench-top biochip system
 measures and analyzes biomolecular and chemical interactions to enable more
 efficient and accurate research outcomes. The biochip utilizes arrays of
 microcantilevers with customizable surfaces to detect interactions between
 proteins, antibodies, antigens, or DNA. This label-free system provides
 researchers with the ability to create high content assays that deliver real
 time data. More information about Protiveris, their technology, products, and
 services can be found at the company's web site at
     About the Lombardi Comprehensive Cancer Center
     Established in 1970, the Lombardi Comprehensive Cancer Center is named for
 the legendary Green Bay Packers and Washington Redskins coach Vince Lombardi,
 who was treated for cancer at Georgetown University Hospital. What began as a
 small clinic grew over the years to become a state-of-the-art cancer center.
 In 1990, the Lombardi Center won the designation of "Comprehensive Cancer
 Center" from the National Cancer Institute (NCI). To obtain this designation,
 a center must meet strict research, clinical trials and community outreach
 criteria. In 2003, Lombardi's comprehensive cancer center status was renewed
 by the NCI. Lombardi's internationally renowned clinical team offers the
 latest treatments for virtually every type of cancer, with a particular
 emphasis in solid tumors and adult and pediatric hematologic cancers. More
 information about Lombardi Comprehensive Cancer Center can be found at

SOURCE Protiveris Inc.